JP2021520788A5 - - Google Patents
Info
- Publication number
- JP2021520788A5 JP2021520788A5 JP2020555033A JP2020555033A JP2021520788A5 JP 2021520788 A5 JP2021520788 A5 JP 2021520788A5 JP 2020555033 A JP2020555033 A JP 2020555033A JP 2020555033 A JP2020555033 A JP 2020555033A JP 2021520788 A5 JP2021520788 A5 JP 2021520788A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- sequence
- cell
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655725P | 2018-04-10 | 2018-04-10 | |
| US62/655,725 | 2018-04-10 | ||
| PCT/US2019/026840 WO2019200007A1 (en) | 2018-04-10 | 2019-04-10 | Chimeric receptors to dll3 and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021520788A JP2021520788A (ja) | 2021-08-26 |
| JP2021520788A5 true JP2021520788A5 (cg-RX-API-DMAC7.html) | 2022-04-18 |
| JP7479290B2 JP7479290B2 (ja) | 2024-05-08 |
Family
ID=66248863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020555033A Active JP7479290B2 (ja) | 2018-04-10 | 2019-04-10 | Dll3に対するキメラ受容体及びその使用方法 |
Country Status (27)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118126157A (zh) | 2017-08-03 | 2024-06-04 | 美国安进公司 | 白介素-21突变蛋白和治疗方法 |
| MX2020007291A (es) | 2018-01-12 | 2020-09-10 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento. |
| EP4527466A3 (en) | 2019-07-17 | 2025-06-18 | Legend Biotech Ireland Limited | Anti-dll3 chimeric antigen receptors and uses thereof |
| US20230272035A1 (en) * | 2019-12-05 | 2023-08-31 | Vycellix, Inc. | Modulators of the immune escape mechanism for universal cell therapy |
| TW202200615A (zh) | 2020-03-12 | 2022-01-01 | 美商安進公司 | 用於治療和預防患者的crs之方法 |
| WO2021180215A1 (en) | 2020-03-12 | 2021-09-16 | Nanjing Legend Biotech Co., Ltd. | Glypican-2-binding moieties, chimeric antigen receptors and uses thereof |
| US20240150456A1 (en) * | 2021-04-02 | 2024-05-09 | Nanjing Legend Biotech Co., Ltd. | Engineered immune cells and uses thereof |
| US20240239878A1 (en) * | 2021-05-08 | 2024-07-18 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Binding molecule against dll3 and use thereof |
| WO2022240688A1 (en) * | 2021-05-10 | 2022-11-17 | Amgen Inc. | Dosing regimen for combination therapy targeting dll3 and pd-1 |
| EP4370541A1 (en) | 2021-07-14 | 2024-05-22 | 2seventy bio, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
| CA3230627A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting dll3 and uses thereof |
| CA3245384A1 (en) | 2022-03-03 | 2023-09-07 | Cambridge Enterprise Limited | Therapeutic antibodies |
| AU2023248532A1 (en) | 2022-04-08 | 2024-11-21 | Regeneron Pharmaceuticals, Inc. | Multipartite receptor and signaling complexes |
| WO2023199069A1 (en) | 2022-04-14 | 2023-10-19 | Crescendo Biologics Limited | Chimeric antigen receptor that binds mesothelin |
| WO2024026284A2 (en) * | 2022-07-25 | 2024-02-01 | Interius Biotherapeutics, Inc. | Mutated polypeptides, compositions comprising the same, and uses thereof |
| CN116003628B (zh) * | 2022-08-15 | 2026-08-04 | 南京博安生物技术有限公司 | 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用 |
| CN116813784B (zh) * | 2023-05-17 | 2024-03-01 | 星奕昂(上海)生物科技有限公司 | 靶向dll3的抗体及其应用 |
| KR20260079181A (ko) * | 2023-09-26 | 2026-06-01 | 레전드 바이오테크 유에스에이, 인크. | Dll3 결합 모이어티 및 이의 용도 |
| CN122094981A (zh) * | 2023-10-16 | 2026-05-26 | 上海先博生物科技有限公司 | 一种靶向δ样配体3的CAR及应用 |
| GB202402046D0 (en) | 2024-02-14 | 2024-03-27 | Bivictrix Ltd | Therapeutic antibodies |
| GB202402048D0 (en) | 2024-02-14 | 2024-03-27 | Bivictrix Ltd | Therapeutic antibodies |
| WO2025202653A1 (en) | 2024-03-27 | 2025-10-02 | Ucl Business Ltd | T-cell therapy targetting mutant calreticulin |
| WO2026039940A1 (zh) * | 2024-08-19 | 2026-02-26 | 南京博安生物技术有限公司 | 一种增强型靶向dll3蛋白的嵌合抗原受体和突变体以及应用 |
| GB202412771D0 (en) | 2024-08-30 | 2024-10-16 | Cambridge Entpr Ltd | Therapeutic molecules |
| CN119241712B (zh) * | 2024-12-05 | 2025-05-06 | 晟临生物医药(上海)有限公司 | 抗dll3的纳米抗体、嵌合抗原受体及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7229960B2 (en) * | 2000-11-03 | 2007-06-12 | University Of Vermont And State Agricultural College | Methods and compositions for inhibiting GRB7 |
| US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US9024028B2 (en) | 2011-01-26 | 2015-05-05 | Ariad Pharmaceuticals, Inc. | Methods and compositions for the synthesis of multimerizing agents |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| JP6267644B2 (ja) * | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗cd22キメラ抗原受容体 |
| CN104520324A (zh) * | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | Dll3调节剂及其使用方法 |
| IL305629A (en) | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
| CA2905352A1 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| EP3027204B1 (en) | 2013-07-29 | 2022-01-05 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| WO2015090229A1 (en) | 2013-12-20 | 2015-06-25 | Novartis Ag | Regulatable chimeric antigen receptor |
| KR20240164967A (ko) | 2014-02-04 | 2024-11-21 | 카이트 파마 인코포레이티드 | B 세포 악성종양 및 다른 암을 치료하는데 유용한 자가 t 세포 및 그의 조성물의 생산 방법 |
| EP3104866A4 (en) | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
| AU2017240801A1 (en) * | 2016-04-01 | 2018-10-25 | Amgen Inc. | Chimeric receptors to FLT3 and methods of use thereof |
| CN107400168B (zh) * | 2017-07-18 | 2020-02-07 | 深圳市免疫基因治疗研究院 | 一种基于cd117的嵌合抗原受体及其应用 |
-
2019
- 2019-04-10 CR CR20200539A patent/CR20200539A/es unknown
- 2019-04-10 PE PE2020001573A patent/PE20211396A1/es unknown
- 2019-04-10 AU AU2019251473A patent/AU2019251473A1/en not_active Abandoned
- 2019-04-10 CN CN201980025035.1A patent/CN112334193A/zh active Pending
- 2019-04-10 AR ARP190100947A patent/AR114283A1/es unknown
- 2019-04-10 JP JP2020555033A patent/JP7479290B2/ja active Active
- 2019-04-10 US US17/046,731 patent/US12012462B2/en active Active
- 2019-04-10 EP EP19719132.3A patent/EP3773912A1/en active Pending
- 2019-04-10 MY MYPI2020005283A patent/MY203383A/en unknown
- 2019-04-10 WO PCT/US2019/026840 patent/WO2019200007A1/en not_active Ceased
- 2019-04-10 IL IL277735A patent/IL277735B1/en unknown
- 2019-04-10 CA CA3095920A patent/CA3095920A1/en active Pending
- 2019-04-10 TW TW108112560A patent/TWI842703B/zh active
- 2019-04-10 UY UY0001041150A patent/UY41150A/es unknown
- 2019-04-10 JO JOP/2020/0259A patent/JOP20200259A1/ar unknown
- 2019-04-10 UY UY38182A patent/UY38182A/es active IP Right Grant
- 2019-04-10 KR KR1020207032081A patent/KR102951376B1/ko active Active
- 2019-04-10 UA UAA202007138A patent/UA129466C2/uk unknown
- 2019-04-10 MX MX2020010753A patent/MX2020010753A/es unknown
- 2019-04-10 BR BR112020020857-4A patent/BR112020020857A2/pt unknown
- 2019-04-10 SG SG11202009923TA patent/SG11202009923TA/en unknown
- 2019-04-10 EA EA202092417A patent/EA202092417A1/ru unknown
- 2019-04-10 MA MA052203A patent/MA52203A/fr unknown
-
2020
- 2020-10-08 SA SA520420301A patent/SA520420301B1/ar unknown
- 2020-10-09 PH PH12020551671A patent/PH12020551671A1/en unknown
- 2020-10-09 CL CL2020002613A patent/CL2020002613A1/es unknown
- 2020-10-23 CO CONC2020/0013392A patent/CO2020013392A2/es unknown
- 2020-11-06 ZA ZA2020/06943A patent/ZA202006943B/en unknown
-
2023
- 2023-03-28 CL CL2023000895A patent/CL2023000895A1/es unknown
- 2023-03-28 CL CL2023000896A patent/CL2023000896A1/es unknown
-
2026
- 2026-01-20 AU AU2026200393A patent/AU2026200393A1/en active Pending